Paliperidone 6 mg (Extended-Release Tablets)

Paliperidone is an atypical antipsychotic (the active metabolite of risperidone used to treat schizophrenia and schizoaffective disorder. It works by blocking dopamine (D₂) and serotonin (5-HT₂A) receptors (also weakly blocking α₁-adrenergic and H₁-histamine receptors). The 6 mg extended-release (ER) tablet (brand name Invega) is designed for once-daily oral dosing. The tablet uses an OROS osmotic system to release medication steadily over 24 hours.

Indications: Paliperidone ER is approved for schizophrenia in adults and in adolescents (12–17 years old, FDA; ≥15 years in some regions). It is also approved for schizoaffective disorder in adults, either as monotherapy or together with mood stabilizers/antidepressants. (It is not indicated for dementia-related psychosis; using any antipsychotic in elderly dementia patients carries a boxed warning due to increased mortality.)

Dosage and Administration

• Typical dosing: The usual starting dose is 6 mg once daily in the morning (range 3–12 mg/day depending on response). No initial titration is needed for most patients – dose increases (by ~3 mg) are made only after at least 5 days if symptoms need further control. For schizophrenia, 6 mg/day is standard; for schizoaffective disorder, dosing is similar (6 mg initial, up to 12 mg). The tablet should be swallowed whole with water – it must not be chewed, split, or crushed. (The tablet’s outer shell passes through the GI tract intact; patients may see a shell-like object in stool.)
• Administration with Food: Paliperidone ER can be taken with or without food, but consistency is key. The prescribing information advises taking the drug always either in a fasting state or always with breakfast, not alternating between fed and fasting states. This ensures steady absorption.
• Special populations: Oral paliperidone is not recommended in children <12 years (schizophrenia) or <18 years (schizoaffective) due to safety/efficacy not established. In elderly patients (>65), use the same adult doses unless kidney function is impaired.
• Renal impairment: Because paliperidone is eliminated by the kidneys, dose adjustment is needed for renal dysfunction. For moderate/severe impairment (CrCl 10–49 mL/min), the dose should generally start at 3 mg/day (administration every other day can be used) rather than 6 mg. (In mild impairment, a provider may start at 3 mg and increase to 6 mg if tolerated.) Paliperidone is not recommended if CrCl <10 mL/min. No dose change is needed for mild-to-moderate liver impairment, but use caution if severe.

Side Effects and Safety

Common side effects of paliperidone (those occurring in ≥5–10% of patients) include extrapyramidal symptoms (EPS) (movement disorders such as parkinsonism, dystonia), akathisia (restless legs), tachycardia, somnolence (sleepiness), and weight gain. Patients often report headache, insomnia, anxiety, dizziness, nausea, constipation, dry mouth, and fatigue . In adolescents, somnolence and tremor are also very common. Metabolic effects are important: paliperidone can cause hyperglycemia, dyslipidemia and significant weight gain，so body weight, fasting glucose, and cholesterol should be monitored regularly. Prolactin levels typically rise (since D₂ blockade increases prolactin), which may lead to menstrual disturbances, galactorrhea, or sexual side effects.

Serious but less common reactions include:

• Tardive dyskinesia: Involuntary movements that may persist; if symptoms appear, discontinuation should be considered.
• Neuroleptic Malignant Syndrome (NMS): Rarely, a life-threatening condition (fever, rigidity, autonomic instability) can occur; if suspected, stop paliperidone immediately and treat supportively.
• Orthostatic hypotension: Some patients experience dizziness or fainting upon standing, especially at treatment initiation or dose changes. Caution in those with cardiovascular disease.
• Metabolic syndrome: As noted, watch for new-onset or worsening diabetes, and manage lipids as needed.
• Hyperprolactinemia: Chronic paliperidone use raises prolactin, so look for prolactin-related effects (gynecomastia, decreased bone density in long term).
• QT prolongation: Paliperidone can lengthen the QT interval modestly. Avoid use with other QT-prolonging drugs (e.g. certain antiarrhythmics, some antibiotics like moxifloxacin) or in patients with pre-existing QT risk.
• Blood disorders: Leukopenia/neutropenia and very rarely agranulocytosis have been reported with antipsychotics. Baseline CBC is not required for all patients, but watch for unexplained fever or infection signs.

Boxed warning: As with other atypical antipsychotics, paliperidone has a black-box warning that use in elderly dementia patients increases mortality (mostly cardiovascular or infectious causes). Paliperidone ER is contraindicated for dementia-related psychosis.

For example, in controlled trials the most frequent adverse events in adults on paliperidone were headache, insomnia/sedation, parkinsonism, akathisia, tachycardia, tremor, dystonia, anxiety, dizziness, weight gain, nausea, and gastrointestinal upset .

Drug Interactions and Precautions

• CNS depressants: Paliperidone can enhance the effects of alcohol, opioids, benzodiazepines or other sedating drugs. Patients should avoid alcohol and be cautious with other CNS depressants.
• Hypotensive agents: Additive blood pressure lowering can occur with antihypertensives or nitrates; monitor blood pressure closely if combined.
• Anticholinergic/CNS drugs: Caution with sedation- or seizure-lowering combinations. Paliperidone may lower seizure threshold, so use carefully in epileptic patients.
• CYP/P-glycoprotein: Paliperidone is minimally metabolized by CYP enzymes but is a substrate for P-glycoprotein. Strong P-gp/CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampin, St. John's wort) can significantly reduce paliperidone levels; doses may need to be increased if these drugs are used. Conversely, stopping an inducer may require lowering the paliperidone dose. Strong inhibitors of P-gp (e.g. ketoconazole) may raise paliperidone levels, although dose adjustment is typically not specified (use with caution).
• Other psychotropics: Combining paliperidone with other dopamine antagonists (like risperidone) is generally avoided due to additive effects . Divalproex sodium (valproate) can increase paliperidone exposure by ~50%; clinical monitoring is advised if used together.

Contraindications: Paliperidone ER should not be used in patients with a known hypersensitivity to paliperidone or risperidone (paliperidone is the primary active metabolite of risperidone). It is also contraindicated in patients with severe renal impairment (CrCl <10 mL/min) or history of neuroleptic malignant syndrome.

Pregnancy & Lactation: Paliperidone is not recommended in pregnancy unless clearly needed. Animal studies did not show birth defects, but neonatal extrapyramidal and withdrawal symptoms have occurred after third-trimester exposure. If used during pregnancy, neonates should be monitored at birth for agitation, hypotonia, tremor or feeding problems. Paliperidone is excreted in human breast milk in significant amounts; breastfeeding during treatment is not recommended.

Monitoring and Advice: Prior to starting, obtain baseline weight, waist circumference, fasting glucose, and lipids. After initiation or dose increases, periodically re-check these parameters due to metabolic risk. Monitor blood pressure for orthostatic changes, and observe for signs of movement disorders. Warn patients that paliperidone can cause dizziness or drowsiness; advise against driving or heavy machinery until they know how it affects them. Inform patients that if they discontinue paliperidone, they should do so gradually under medical supervision to avoid withdrawal (e.g. insomnia, nausea, restlessness).

Summary

Paliperidone 6 mg ER tablets (Invega) are a long-acting antipsychotic used once daily for schizophrenia and schizoaffective disorder. The drug’s extended-release formulation ensures steady medication levels. Typical adult dosing is 6 mg daily (range 3–12 mg), with no food restrictions (though dosing should be consistent relative to meals). Its most common side effects are movement disorders, restlessness, weight gain, sedation, and tachycardia. Serious risks include tardive dyskinesia, neuroleptic malignant syndrome, metabolic syndrome and QT prolongation. Regular monitoring (weight, blood sugar/lipids, blood counts) is advised. Paliperidone ER is contraindicated in those with dementia-related psychosis. Always follow the prescribing physician’s instructions and report any troubling symptoms.